Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Lymphoma, T-Cell × Brentuximab Vedotin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Hodgkin Disease 1 Hematologic Diseases 1 Ann Arbor Stage IIB Hodgkin Lymphoma 1

Interventions

Vincristine 1 Prednisone 1 Doxorubicin 1 Cyclophosphamide 1 Brentuximab Vedotin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01777152 2021-11-30

ECHELON-2

Seagen Inc.

Phase 3 Completed

452 enrolled 16 charts 1 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡